BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35562126)

  • 1. Free PSA performs better than total PSA in predicting prostate volume in Chinese men with PSA levels of 2.5-9.9 ng ml
    Huang MP; Tang P; Klein CS; Wei XH; Du W; Fu JG; Huang TH; Chen H; Xie KJ
    Asian J Androl; 2023; 25(1):82-85. PubMed ID: 35562126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between total/free prostate-specific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia.
    Mao Q; Zheng X; Jia X; Wang Y; Qin J; Yang K; Bai Y; Xie L
    Int Urol Nephrol; 2009 Dec; 41(4):761-6. PubMed ID: 19224388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
    Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
    BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
    Haese A; Graefen M; Steuber T; Becker C; Pettersson K; Piironen T; Noldus J; Huland H; Lilja H
    Prostate; 2001 Oct; 49(2):101-9. PubMed ID: 11582588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/mL.
    Okegawa T; Kinjo M; Ohta M; Miura I; Horie S; Nutahara K; Higashihara E
    Int J Urol; 2003 Apr; 10(4):201-6. PubMed ID: 12657099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean population.
    Choi H; Park JY; Shim JS; Kim JH; Bae JH
    Int Neurourol J; 2013 Jun; 17(2):73-7. PubMed ID: 23869271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial.
    Djavan B; Remzi M; Zlotta AR; Ravery V; Hammerer P; Reissigl A; Dobronski P; Kaisary A; Marberger M
    Urology; 2002 Oct; 60(4 Suppl 1):4-9. PubMed ID: 12384156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution.
    Nan LB; Yin XT; Gao JP
    Med Sci Monit; 2019 Nov; 25():8345-8351. PubMed ID: 31691648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential diagnostic value of multiple indicators combined with total prostate-specific antigen in prostate cancer.
    Zhang Q; Li H; Song Z; Kong S; Zhao S; Fan S; Qin F; Ma J
    J Int Med Res; 2023 Oct; 51(10):3000605231204429. PubMed ID: 37848343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
    Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
    Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer.
    Okegawa T; Noda H; Nutahara K; Higashihara E
    Eur Urol; 2000 Oct; 38(4):380-7. PubMed ID: 11025374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-specific prostate specific antigen cutoffs for guiding biopsy decision in Chinese population.
    Na R; Wu Y; Xu J; Jiang H; Ding Q
    PLoS One; 2013; 8(6):e67585. PubMed ID: 23825670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of the prostate health index in predicting the presence and aggressiveness of prostate cancer among Korean men: a prospective observational study.
    Kim JY; Yu JH; Sung LH; Cho DY; Kim HJ; Yoo SJ
    BMC Urol; 2021 Sep; 21(1):131. PubMed ID: 34530786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate Health Index outperforms other PSA derivatives in predicting a positive biopsy in men with tPSA <10 ng/mL: Largest prospective cohort in Taiwan.
    Fan YH; Pan PH; Lin TP; Huang TH; Wei TC; Huang IS; Lin CC; Huang EYH; Chung HJ; Huang WJS
    J Chin Med Assoc; 2019 Oct; 82(10):772-777. PubMed ID: 31356566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of histological inflammation on total and free serum prostate-specific antigen values in patients without clinically detectable prostate cancer.
    Stimac G; Spajic B; Reljic A; Katusic J; Popovic A; Grubisic I; Tomas D
    Korean J Urol; 2014 Aug; 55(8):527-32. PubMed ID: 25132947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of prostate cancer in African-American men through use of multiple biomarkers: human kallikrein 2 (hK2), prostate-specific antigen (PSA), and free PSA (fPSA).
    Martin BJ; Finlay JA; Sterling K; Ward M; Lifsey D; Mercante D; Jainto JM; Martin L; Rayford W
    Prostate Cancer Prostatic Dis; 2004; 7(2):132-7. PubMed ID: 15007379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).
    Chen R; Zhou LQ; Cai XB; Xie LP; Huang YR; He DL; Gao X; Xu CL; Ding Q; Wei Q; Yin CJ; Ren SC; Wang FB; Tian Y; Sun ZQ; Fu Q; Ma LL; Zheng JH; Ye ZQ; Ye DW; Xu DF; Hou JQ; Xu KX; Yuan JL; Gao X; Liu CX; Pan TJ; Sun YH;
    Asian J Androl; 2015; 17(6):1017-21. PubMed ID: 25926603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.